Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines ...

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

CNBC's Jim Cramer talks about his take on Moderna's stock performance and business outlook.

CNBC's Jim Cramer talks about his take on Moderna's stock performance and business outlook.

Moderna (MRNA) shares rallied on June 26 after the company detailed its future beyond COVID-19 at its highly anticipated ...

Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to ...

Provides broad overview of Company's research and early development programs expected to continue to fuel future ...

Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the ...

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class ...

Moderna (MRNA) stock jumps on Science Day pipeline update and FDA flu vaccine vote; see key catalysts, technical levels, and ...

Moderna (MRNA) has been struggling to shake one label for years: Covid winner. That label helped to make the company famous, ...

The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to ...